Drug intelligence / Profile preview

Xerorinse

Development stage: Preclinical
Lead developer: Oak Therapeutics
Modality: Small Molecules
Administration: Oral, Buccal, Sublingual

Overview

Xerorinse is an oral dissolvable strip (ODS) formulation developed by Oak Therapeutics for anti-plaque applications in dental and oral health. The product utilizes a proprietary thin-film technology designed for precision-controlled drug release and high loading capacity, dissolving when placed on the tongue or inside the cheek. Currently in the preclinical proof-of-concept stage, Xerorinse is intended to provide a targeted delivery method for anti-plaque agents, though the specific active pharmaceutical ingredient and biological target have not been publicly disclosed. The ODS platform aims to offer a more convenient and precise alternative to traditional oral rinses or gels for maintaining dental hygiene and preventing plaque accumulation.

Brand names: Xerorinse

Beyond the preview

Go deeper on Xerorinse.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xerorinse.

Explore the full profile